Drug intelligence / Profile preview

MCS2104

Development stage: Preclinical
Lead developer: PharmaCept
Modality: Hydrogel Systems → Drug Delivery Systems, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

**MCS2104** is a conceptual-stage Magle Pharmacept regenerative-medicine candidate in the GelSpheres program. It is described as a new composition for dental bone tissue engineering that incorporates an mRNA molecule intended to induce and facilitate tissue repair and regeneration by accelerating normal physiological repair processes. The specific mRNA sequence, molecular target, delivery composition, route of administration, and clinical indication have not been publicly disclosed. ([maglepharmacept.com](https://maglepharmacept.com/our-pipeline/))

Beyond the preview

Go deeper on MCS2104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MCS2104.

Explore the full profile